Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B0fdae5d9d8a3fdeae1b1922d06fd5561> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B0fdae5d9d8a3fdeae1b1922d06fd5561 NCIT_P378 "NCI" @default.
- B0fdae5d9d8a3fdeae1b1922d06fd5561 type Axiom @default.
- B0fdae5d9d8a3fdeae1b1922d06fd5561 annotatedProperty IAO_0000115 @default.
- B0fdae5d9d8a3fdeae1b1922d06fd5561 annotatedSource NCIT_C185875 @default.
- B0fdae5d9d8a3fdeae1b1922d06fd5561 annotatedTarget "An orally bioavailable degrader of casein kinase 1 alpha (CK1alpha; CK1a), with potential antineoplastic activity. Upon oral administration, CK1a degrader CC-91633 binds to and degrades CK1a, thereby inhibits the activity of CK1a. This prevents the enhanced binding of murine double minute X (MDMX) to p53, reduces the formation of CK1a and MDM2 complex, and prevents the interaction of MDM2 with p53. This prevents the inhibition of p53 and increases p53 activity. This induces p53-mediated cell cycle arrest, thereby inhibiting tumor cell proliferation. CK1a, a serine/threonine kinase and a leukemic stem cell target, acts as a tumor suppressor in several cancers through the negative regulation of Wnt/beta-catenin signaling and p53. It negatively regulates p53 by phosphorylating MDMX, thus enhancing binding of MDMX to p53, as well as by forming a complex with MDM2." @default.